SCHEMBL11943642

SCHEMBL11943642

N#Cc1cccc(-c2c(N3CCN(S(=O)(=O)Cc4ccccc4)CC3)cnn(-c3cc(F)cc(F)c3)c2=O)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 2/20 0.42
▸ KMT2A Q03164 1/20 0.40
▸ CYP3A4 P08684 3/20 0.38
▸ CYP2C19 P33261 2/20 0.38
▸ POLB P06746 1/20 0.38
▸ PPARG P37231 1/20 0.38
▸ NCOA2 Q15596 1/20 0.38
▸ NCOA1 Q15788 1/20 0.38
▸ NPSR1 Q6W5P4 1/20 0.38
▸ NCOA3 Q9Y6Q9 1/20 0.38
▸ MMP13 P45452 1/20 0.38
▸ MMP14 P50281 1/20 0.38
▸ ALDH1A1 P00352 5/20 0.37
▸ MAPK1 P28482 1/20 0.37
▸ DCTPP1 Q9H773 1/20 0.37
▸ LMNA P02545 3/20 0.36
▸ USP2 O75604 2/20 0.36
▸ TP53 P04637 2/20 0.36
▸ CASP1 P29466 2/20 0.36
▸ CASP7 P55210 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11943659 0.92 MAPT (0.44) MAPTKMT2ACYP3A4CYP2C19POLB
SCHEMBL11943751 0.90 MAPT (0.46) MAPTCYP3A4CYP2C19POLBPPARG
SCHEMBL11943638 0.90 MAPT (0.49) MAPTCYP3A4CYP2C19POLBPPARG
SCHEMBL11943720 0.88 MAPT (0.48) MAPTCYP3A4CYP2C19POLBPPARG
SCHEMBL11943708 0.88 MAPT (0.49) MAPTCYP3A4CYP2C19POLBPPARG
SCHEMBL11943667 0.88 MAPT (0.46) MAPTKMT2ACYP3A4CYP2C19POLB
SCHEMBL11943718 0.88 POLB (0.49) MAPTCYP3A4CYP2C19POLBPPARG
SCHEMBL11943746 0.86 MAPT (0.48) MAPTCYP3A4CYP2C19POLBPPARG
SCHEMBL11943719 0.86 MAPT (0.43) MAPTKMT2ACYP3A4CYP2C19POLB
SCHEMBL11943734 0.86 MAPT (0.45) MAPTKMT2ACYP3A4CYP2C19POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8232274-B2 Pyridazinone derivatives useful as glucan synthase inhibitors ALBANY MOLECULAR RESEARCH, INC. (US) 2012-07-31 — — US disclosed
US-8232274-B2 Pyridazinone derivatives useful as glucan synthase inhibitors ALBANY MOLECULAR RESEARCH, INC. (US) 2012-07-31 — — US disclosed
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors SCHERING CORPORATION AND ALBANY MOLECULAR RESEARCH, INC. 2009-07-02 — — US disclosed
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors SCHERING CORPORATION AND ALBANY MOLECULAR RESEARCH, INC. 2009-07-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors MAN2A1, GYS2, MANBA MAPT 2295/4885KMT2A 3312/4885CYP3A4 281/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback